| Small molecules enhance autophagy and reduce toxicity in Huntington's disease models S Sarkar, EO Perlstein, S Imarisio, S Pineau, A Cordenier, RL Maglathlin, ... Nature chemical biology 3 (6), 331-338, 2007 | 697 | 2007 |
| Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ M Sharma, AH Beck, JA Webster, I Espinosa, K Montgomery, S Varma, ... Breast cancer research and treatment 123, 397-404, 2010 | 117 | 2010 |
| Acute myeloid leukemia in the elderly: therapeutic options and choice JA Webster, KW Pratz Leukemia & lymphoma 59 (2), 274-287, 2018 | 99 | 2018 |
| Phase II trial of pembrolizumab after high-dose cytarabine in relapsed/refractory acute myeloid leukemia JF Zeidner, BG Vincent, A Ivanova, D Moore, KP McKinnon, AD Wilkinson, ... Blood cancer discovery 2 (6), 616-629, 2021 | 65 | 2021 |
| Multi-center phase 2 study of pembroluzimab (Pembro) and azacitidine (AZA) in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed (≥ 65 years … I Gojo, RK Stuart, J Webster, A Blackford, JC Varela, J Morrow, AE DeZern, ... Blood 134, 832, 2019 | 61 | 2019 |
| Chaperone activity of small heat shock proteins underlies therapeutic efficacy in experimental autoimmune encephalomyelitis MP Kurnellas, SE Brownell, L Su, AV Malkovskiy, J Rajadas, G Dolganov, ... Journal of Biological Chemistry 287 (43), 36423-36434, 2012 | 59 | 2012 |
| Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional … JI Zwicker, A Rojan, F Campigotto, N Rehman, R Funches, G Connolly, ... Journal of clinical oncology 32 (17), 1792-1796, 2014 | 57 | 2014 |
| Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia JA Webster, R Tibes, L Morris, AL Blackford, M Litzow, M Patnaik, ... Leukemia research 61, 108-116, 2017 | 56 | 2017 |
| Blinatumomab in combination with immune checkpoint inhibitors of PD-1 and CTLA-4 in adult patients with relapsed/refractory (R/R) CD19 positive B-cell acute lymphoblastic … J Webster, MR Luskin, GT Prince, AE DeZern, DJ DeAngelo, MJ Levis, ... Blood 132, 557, 2018 | 51 | 2018 |
| Variations in stromal signatures in breast and colorectal cancer metastases JA Webster, AH Beck, M Sharma, I Espinosa, B Weigelt, M Schreuder, ... The Journal of pathology 222 (2), 158-165, 2010 | 39 | 2010 |
| Treatment of AML relapse after allo-HCT JA Webster, L Luznik, I Gojo Frontiers in Oncology 11, 812207, 2021 | 32 | 2021 |
| Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide JA Webster, L Luznik, HL Tsai, PH Imus, AE DeZern, KW Pratz, MJ Levis, ... Blood Advances 4 (20), 5078-5088, 2020 | 32 | 2020 |
| Final clinical results of a phase II study of high dose cytarabine followed by pembrolizumab in relapsed/refractory AML JF Zeidner, BG Vincent, S Esparza, A Ivanova, DT Moore, MC Foster, ... Blood 134, 831, 2019 | 32 | 2019 |
| Mobile app validation: a digital health scorecard approach R Sedhom, MJ McShea, AB Cohen, JA Webster, SC Mathews NPJ Digital Medicine 4 (1), 111, 2021 | 30 | 2021 |
| Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia C Sterling, J Webster American journal of hematology 95 (5), 529-547, 2020 | 22 | 2020 |
| The case for real-world evidence in the future of clinical research on chronic myeloid leukemia J Webster, BD Smith Clinical therapeutics 41 (2), 336-349, 2019 | 22 | 2019 |
| Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis T Jain, HL Tsai, AE DeZern, LP Gondek, H Elmariah, J Bolaños-Meade, ... Transplantation and cellular therapy 28 (5), 259. e1-259. e11, 2022 | 20 | 2022 |
| Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving … S Kayser, C Sartor, MR Luskin, J Webster, F Giglio, N Panitz, AM Brunner, ... Haematologica 107 (9), 2064, 2022 | 15 | 2022 |
| Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo ND Vincelette, H Ding, AM Huehls, KS Flatten, RL Kelly, MA Kohorst, ... Scientific reports 9 (1), 3617, 2019 | 14 | 2019 |
| Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction BC Hambley, KJ Norsworthy, J Jasem, JW Zimmerman, E Shenderov, ... Leukemia research 83, 106174, 2019 | 11 | 2019 |
Keith PratzUniversity of Pennsylvania在 pennmedicine.upenn.edu 的电子邮件经过验证
